Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis

Kong, Li; Zuo, Kai; Ma, Liang

doi:10.12669/pjms.36.7.1964

Cited by 6 publications

(10 citation statements)

References 13 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a significant change in BMD is rarely observed in patients receiving only Bd treatment, and the total effective rate is relatively low. 21 , 22 , 23 Bisphosphonates can improve BMD by inhibiting the activity of osteoclasts. They have been on the market for a long time and have reliable effects.…”

Section: Discussionmentioning

confidence: 99%

“…They have been on the market for a long time and have reliable effects. 23 , 24 For patients newly diagnosed with PMOP, antiresorptive drugs are recommended before bone-forming drugs, according to guidelines. 25 Therefore, bisphosphonate drugs have been widely used in China.…”

Section: Discussionmentioning

confidence: 99%

“…Calcium, vitamin D, and calcitriol are considered Bds for this treatment. However, a significant change in BMD is rarely observed in patients receiving only Bd treatment, and the total effective rate is relatively low 21,22,23 . Bisphosphonates can improve BMD by inhibiting the activity of osteoclasts.…”

Section: Discussionmentioning

confidence: 99%

“…Bisphosphonates can improve BMD by inhibiting the activity of osteoclasts. They have been on the market for a long time and have reliable effects 23,24 . For patients newly diagnosed with PMOP, antiresorptive drugs are recommended before bone-forming drugs, according to guidelines 25 .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Declining serum bone turnover markers are associated with the short-term positive change of lumbar spine bone mineral density in postmenopausal women

Zhao

Wen

et al. 2022

Menopause

View full text Add to dashboard Cite

Objective: While serum bone turnover markers (BTMs) and bone mineral density (BMD) have been confirmed as useable risk assessment tools for postmenopausal osteoporosis, the associations between BTMs and BMD changes are still ambiguous. The aim of this study was to explore the underlying associations between BTMs and BMD changes in postmenopausal women. Methods: Between January 2015 and October 2020, 135 postmenopausal women were retrospectively enrolled. They were divided into two groups according to lumbar spine (LS) 1-4 BMD change (1 y T-score minus baseline T-score, Group 1 [ n = 36] < 0 and Group 2 [ n = 99] ≥ 0). The changes of BTMs (N-terminal middle segment osteocalcin [N-MID], propeptide of type I procollagen [P1NP], and β-C-terminal telopeptide of type I collagen [β-CTX]) and their associations with LS 1-4 BMD change were analyzed. The biochemical indices and clinical parameters related with LS 1-4 BMD change were also evaluated. Results: The 1 year N-MID, P1NP, β-CTX and Phosphorus in Group 2 were lower than those in Group 1 ( P < 0.05), their changes within 1 year were significantly negatively correlated with LS 1-4 BMD change ( R 2 = –0.200, P < 0.001; R 2 = –0.230, P < 0.001; R 2 = –0.186, P < 0.001; R 2 = –0.044, P = 0.015; respectively). Except for the Phosphorus change (area under the curve [AUC] = 0.623), the changes of N-MID, P1NP, and β-CTX and their 1 year levels had similar AUC to diagnose the short-term LS 1-4 BMD change (AUC > 0.7 for all, with the AUC of 1 y P1NP being the largest at 0.803). Binary logistic regression analysis showed that the physical activity and drug intervention were the determinant factors for the LS 1-4 BMD change (odds ratio = 6.856, 95% confidence interval: 2.058-22.839, P = 0.002; odds ratio = 5.114, 95% confidence interval: 1.551-16.864, P = 0.007; respectively). Conclusions: Declining N-MID, P1NP, β-CTX, and Phosphorus are associated with the short-term increase of LS 1-4 BMD within 1 year. Physical activity and drug intervention are factors significantly influencing the change of LS 1-4 BMD in postmenopausal women.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Declining serum bone turnover markers are associated with the short-term positive change of lumbar spine bone mineral density in postmenopausal women

Zhao

Wen

et al. 2022

Menopause

View full text Add to dashboard Cite

show abstract

“…Among the bisphosphonates, ZA has been shown to have better persistence, and once-yearly intravenous injections is effective in improving osteoporosis ( Fobelo Lozano and Sánchez-Fidalgo, 2019 ). ZA is helpful to alleviate clinical symptoms, reduce the degree of bone pain, promote the increase of bone mass, and has a high safety for the treatment of senile osteoporosis, which is the favored treatment for osteoporosis ( Kong et al, 2020 ). The excellent anti-osteoporosis effect of ZA is mainly attributed to its ability to specifically inhibit osteoclast-mediated bone resorption and osteoclast activation, and even act directly on osteoclasts to inhibit their formation, thereby accelerating osteoclast apoptosis and increasing bone mineral density ( Fobelo Lozano and Sánchez-Fidalgo, 2019 ; Kong et al, 2020 ).…”

Section: New Directions and Hot Spots In Research Of Zoledronic Acidmentioning

confidence: 99%

How zoledronic acid improves osteoporosis by acting on osteoclasts

et al. 2022

View full text Add to dashboard Cite

Osteoporosis is called a silent disease, because it is difficult to detect until comprehensive examinations for osteoporosis are performed or osteoporotic fractures occur. Zoledronic acid is currently the first-line anti-osteoporotic drug, with good efficacy and treatment compliance. A major advantage of zoledronic acid is that intravenous zoledronic acid often guarantees a therapeutic effect for up to 1 year after infusion. The reasons why zoledronic acid is effective in improving osteoporosis are that it can inhibit osteoclast differentiation and induce osteoclast apoptosis, thus suppressing bone resorption and increasing bone density. The story between zoledronic acid and osteoclasts has been written long time ago. Both the canonical receptor activator of the receptor activator of nuclear factor-κB ligand (RANKL) pathway and the non-canonical Wnt pathway are the main pathways by which zoledronic acid inhibits osteoclast differentiation. Farnesyl pyrophosphate synthase (FPPS), reactive oxygen species (ROS), and ferroptosis that was first proposed in 2012, are all considered to be closely associated with zoledronic acid-induced osteoclast apoptosis. Here, we provide a brief review of the recent progress on the study of zoledronic acid and osteoclasts, and hope to elaborate how zoledronic acid improves osteoporosis by acting on osteoclasts.

show abstract